8-K: Agilent Technologies Announces Segment Reporting Changes Following Organizational Restructure

Agilent Technologies recasts its financial segments to align with its new market-focused, customer-centric strategy, combining and moving divisions to form three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.

Summary

• Agilent Technologies has announced a change in its organizational structure, leading to a recasting of its segment reporting.
• The former Diagnostics and Genomics segment is now combined with liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form the Life Sciences and Diagnostics Markets segment.
• Chemistries and supplies, laboratory automation, and software and informatics divisions have moved from the former Life Sciences and Applied Markets segment to the Agilent CrossLab segment.
• The remaining divisions in the former Life Sciences and Applied Markets segment, including gas chromatography, gas chromatography mass spectrometry, remarketed instruments, spectroscopy, and vacuum divisions, will form the new Applied Markets segment.
• Following this reorganization, Agilent now has three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
• Historical financial segment information has been recast to conform to this new presentation.
• In November 2024, Agilent announced a change in its organizational structure to support its market-focused, customer-centric strategy.
• The former Diagnostics and Genomics segment combined with our liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form our new Life Sciences and Diagnostics Markets segment.
• Our chemistries and supplies, laboratory automation, and software and informatics divisions moved from our former Life Sciences and Applied Markets segment to our Agilent CrossLab segment.
• The remaining divisions in our former Life Sciences and Applied Markets segment which includes our gas chromatography, gas chromatography mass spectrometry, remarketed instruments, spectroscopy and vacuum divisions will form our new Applied Markets segment.
• Following this re-organization, we have three business segments Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets, each of which comprise a reportable segment.

Sentiment

Score: 7

Explanation: The document is primarily informational, detailing a reorganization and recasting of financial segments. While it acknowledges challenges like constrained customer budgets, it expresses optimism about long-term growth and market recovery. The sentiment is neutral to slightly positive.

Positives

• The reorganization aims to support Agilent's market-focused, customer-centric strategy.
• The Agilent CrossLab segment provides an extensive services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represents a broad range of offerings designed to serve customer needs across end-markets and applications.

Risks

• The report contains forward-looking statements that involve risks and uncertainties, and actual results could differ materially.
• Climate change may impact Agilent's business by increasing operating costs, disrupting manufacturing processes, and adding regulatory requirements.

Future Outlook

Agilent anticipates a gradual and steady market recovery in the short-term and remains optimistic about the long-term health of its key end markets.

Management Comments

• Looking forward, our primary focus remains on enhancing our customers experience, delivering differentiated product solutions and driving productivity improvements.
• While customer capital budgets continue to be constrained, we anticipate a gradual and steady recovery in the short-term.
• We also remain optimistic about the long-term health of our key end markets.
• Although inflationary pressures are uncertain, we will continue to mitigate their impact through targeted pricing strategies and various other cost-saving initiatives.

Industry Context

The analytical product sets in the Life Sciences and Diagnostics Markets in which Agilent competes are characterized by evolving industry standards and intense competition.

Comparison to Industry Standards

• Agilent's principal competitors in the Life Sciences and Diagnostics Markets arena include AB Sciex, Avecia, Bruker, Leica Biosystems, Roche Ventana Medical Systems, Shimadzu Corporation, Thermo Fisher Scientific Inc., Twist Bioscience Corporation and Waters Corporation.
• Agilent competes on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price.

Stakeholder Impact

• The reorganization may impact employees through workforce reductions and changes in roles.
• Customers may experience changes in how Agilent's products and services are delivered.
• Shareholders may be affected by the company's stock repurchase program and dividend policy.

Next Steps

• Agilent expects to substantially complete the remaining restructuring activities by the end of the second quarter of fiscal year 2025.
• The 2024 repurchase program will commence upon the termination of our 2023 repurchase program.

Key Dates